(s)-(-)-2-羟基-3-苯基丙酸苄酯 | 7622-21-1

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (s)-(-)-2-羟基-3-苯基丙酸苄酯
• 中文别名: (S)-(-)-2-羟基-3-苯丙酸苄酯
• 英文名称: benzyl-(S)-(-)-2-hydroxy-3-phenylpropionate
• 英文别名: (S)-benzyl 2-hydroxy-3-phenylpropanoate；(S)-phenyllactic acid benzyl ester；Benzyl (S)-(-)-2-hydroxy-3-phenylpropionate；benzyl (2S)-2-hydroxy-3-phenylpropanoate
• CAS: 7622-21-1
• 化学式: C₁₆H₁₆O₃
• 分子量: 256.301
• InChiKey: XFULYMQQCZRWQB-HNNXBMFYSA-N

物化性质

• 沸点：
  288 °C(lit.)
• 密度：
  1.142 g/mL at 25 °C(lit.)
• 闪点：
  113 °C
• 稳定性/保质期：

  如果遵照规格使用和储存，则不会分解，未有已知危险发生。应避免与强氧化剂接触。

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 储存条件：
  密闭、阴凉干燥处保存，并确保有良好的通风。

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
: Benzyl (S)-(−)-2-hydroxy-3-phenylpropionate
Product name
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
CAS-No. : 7622-21-1
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
This substance is not classified as dangerous according to Directive 67/548/EEC.
Label elements
Other hazards - none

---

SECTION 3: Composition/information on ingredients
Substances
Formula : C16H16O3
Molecular Weight : 256,30 g/mol
CAS-No. : 7622-21-1
No components need to be disclosed according to the applicable regulations.

---

SECTION 4: First aid measures
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
no data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Avoid breathing vapours, mist or gas.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Normal measures for preventive fire protection.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are
opened must be carefully resealed and kept upright to prevent leakage.
Specific end use(s)
A part from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
impervious clothing, The type of protective equipment must be selected according to the
concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection not required. For nuisance exposures use type OV/AG (US) or type ABEK
(EU EN 14387) respirator cartridges. Use respirators and components tested and approved under
appropriate government standards such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: liquid
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and 288 °C - lit.
boiling range
g) Flash point > 113,00 °C - closed cup
h) Evapouration rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,142 g/cm3 at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Auto-ignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

SECTION 10: Stability and reactivity
Reactivity
no data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitisation
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
PBT/vPvB assessment not available as chemical safety assessment not required/not conducted
Other adverse effects
no data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (s)-(-)-2-羟基-3-苯基丙酸苄酯 在 四丁基碘化铵 lutidine 、 二正丁基氧化锡 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 苯 为溶剂， 反应 26.33h， 生成 (1S,2S,4R,5S)-4-((R)-1-benzyloxycarbonyl-2-phenyl-ethoxy)-5-methoxymethoxy-cyclohexane-1,2-dicarboxylic acid dimethyl ester
  参考文献：
  名称：

  用于研究碳水化合物-芳烃相互作用的简单模型系统

  摘要：

  确定了一种分子支架，它能够在单糖和附近的苯环之间建立分子内相互作用。合成了一组含有四种不同单糖（葡萄糖、半乳糖、N-乙酰-氨基葡萄糖和 N-乙酰-半乳糖）的分子，并用于研究这种碳水化合物-芳烃相互作用的程度和性质，以及对所涉及分子的整体 3D 结构。糖-芳香族距离通过分子模型支持的严格 NMR 研究进行评估，发现在整个系列中是恒定的，与糖的性质和连接两个元素的片段的构象行为无关。B3LYP/DZV(2d,p) 理论水平的从头算计算能够分析相互作用的电子性质。该研究表明，如果有机会，可以建立持久的分子内芳香-糖相互作用，并且可以显着影响整体分子形状和能量。这些结果对寡糖结构模拟物的设计具有重要意义。

  DOI：

  10.1021/ja066633g
• 作为产物：
  描述：

  (S)-2-溴-3-苯基丙酸 在 水 、 sodium carbonate 、 三乙胺 作用下， 以 丙酮 为溶剂， 反应 20.0h， 生成 (s)-(-)-2-羟基-3-苯基丙酸苄酯
  参考文献：
  名称：

  通过系统置换酰胺获得的一系列线性亮氨酸脑啡肽类似物的 Delta 阿片受体的制备和评价

  摘要：

  使用经典有机化学和固相肽合成 (SPPS) 制备亮氨酸脑啡肽类似物，其中酰胺键被酯或N-甲基酰胺键顺序和系统地取代。使用竞争结合、ERK1/2 磷酸化、受体内化和收缩性测定来表征肽模拟物，以评估它们对 delta 阿片受体 (DOPr) 的药理学特征。还测量了活性类似物的亲脂性(LogD 7.4 )和血浆稳定性。我们的结果表明，最后一个酰胺键可以被酯或N成功取代与亮氨酸脑啡肽相比，-甲基酰胺键不会显着降低相应类似物的生物活性。发现在残基 Phe 和 Leu 之间具有N-甲基酰胺功能的肽模拟物比 Leu-脑啡肽更亲脂且更稳定。本研究的结果进一步表明，亮氨酸脑啡肽的第四个酰胺的氢键供体性质对其对 DOPr 的生物活性并不重要。我们的结果表明，用等排功能系统地替换酰胺键代表了一种设计和合成具有增强稳定性的新型肽类似物的有效方法。我们的研究结果进一步表明，这种策略也可用于研究酰胺键的生物学作用。

  DOI：

  10.1021/cn4000583

文献信息

• Solution-Phase Peptide Synthesis; Synthesis of 'North-Western' and 'South-Eastern' Fragments of the Antifungal Cyclodepsipeptide Petriellin A
  作者：Luigi Aurelio、Robert T. C. Brownlee、Andrew B. Hughes

  DOI：10.1071/ch08132

  日期：——

  The solution-phase synthesis of two highly modified peptides, a hexamer and a heptamer, that constitute the two halves of the antifungal cyclic depsipeptide, Petriellin A, is reported.

  本报告介绍了两种高度修饰的肽的溶液相合成过程，一种是六聚体，另一种是七聚体，它们构成了抗真菌环脱肽 Petriellin A 的两半。
• CYCLIC TETRAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS
  申请人：NOVARTIS AG

  公开号：US20200164024A1

  公开（公告）日：2020-05-28

  The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , R 1 , X 1 , X 2 , and X 3 are described herein.

  该披露涉及对PCSK9的抑制剂，用于治疗胆固醇脂质代谢以及其他PCSK9发挥作用的疾病，其化学式为(I)： 或其药用可接受的盐、水合物、溶剂合物、前药、立体异构体、N-氧化物或互变异构体，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X1、X2和X3如本文所述。
• Novel amino acid derivatives possessing renin-inhibitory activities
  申请人：Japan Tobacco Inc.

  公开号：EP0396065A1

  公开（公告）日：1990-11-07

  An amino acid derivative of the general formula: wherein R1 is wherein, R10 is a lower alkyl group and R" is (wherein R111 is a lower alkyl group and n is an integer of 1 to 5) or a lower alkyl group which may be substituted by hydroxy group or methoxyethoxymethoxy group, or R'° and R" are combinedly together with the adjacent nitrogen atom; R12 is a hydrogen atom, CnH2n+1-O-CO- (n is as defined above) or R'3 is a lower alkyl group which may be substituted by substituent(s) selected from HOOC-(H2C)n-O-, R12- NH- (n and R12 are as defined above) and pyridyl group; X is -CH2-, -O- or -NH- and Y is -O- or -NH-; wherein (wherein Z is -0-, -S-, -S(O)-. -S(O)2-, -CH2-, -CH(OH)-, or and a and b are independently an integer of 1 to 4 and the total of a and b is not more than 5) ; R2 is an aralkyl group which may be substituted by lower alkyl group(s); R3 is a hydrogen atom or a lower alkyl group; R4 is a lower alkyl group; and A is hydroxy group and B is a hydrogen atom, or A and B are carbonyl group combinedly together with the adjacent carbon atom, a pharmaceutically acceptable acid addition salt or an ester thereof is described. The compounds of the invention possess inhibitory activities against renin and are useful as an antihypertensive agent.

  通用公式的氨基酸衍生物： 其中R1为 其中，R10为较低的烷基基团，R"为 （其中R111为较低的烷基基团，n为1至5的整数）或者可以被羟基或甲氧乙氧甲氧基取代的较低烷基基团，或者R'°和R"与相邻的氮原子 结合在一起； R12为氢原子，CnH2n+1-O-CO-（n如上定义）或者 R'3为可以被HOOC-(H2C)n-O-、R12-NH-（n和R12如上定义）和吡啶基取代的较低烷基基团； X为-CH2-、-O-或-NH-，Y为-O-或-NH-；其中 （其中Z为-0-、-S-、-S(O)-、-S(O)2-、- -、-CH(OH)-， 或 a和b分别独立为1至4的整数，且a和b的总和不超过5）； R2为可以被较低烷基基团取代的芳基烷基基团； R3为氢原子或较低烷基基团； R4为较低烷基基团； A为羟基，B为氢原子，或者A和B与相邻的碳原子结合在一起，描述了一种药学上可接受的酸盐或其酯。本发明的化合物具有对肾素的抑制活性，并可用作降压药。
• Use of propargyl glycine amino propargyl diol compounds for inhibiting plasma renin activity
  申请人：G. D. Searle & Co.

  公开号：US06342624B1

  公开（公告）日：2002-01-29

  Compounds characterized generally as propargyl glycine amino propargyl diol derivatives are useful for treatment of a disorder mediated by inhibiting plasma renin activity. Compounds of particular interest are those of Formula I wherein A is selected from CO and SO2 wherein X is is selected from oxygen atom and methylene; wherein each of R1 and R9 is a group independently selected from hydrido, methyl, ethyl, n-propyl, isopropyl, benzyl, b, b, b-trifluoroethyl, t-butyloxycarbonyl and methoxymethylcarbonyl, and wherein the nitrogen atom to which R1 and R9 are attached may be combined with oxygen to form an N-oxide; wherein R2 is selected from hydrido, methyl, ethyl and isopropyl; wherein R3 is selected from benzyl, cyclohexylmethyl, phenethyl, imidazolemethyl, pyridylmethyl and 2-pyridylethyl; wherein each of R5 and R8 is independently propargyl or a propargyl-containing moiety; wherein R7 is cyclohexylmethyl; wherein each of R4 and R6 is independently selected from hydrido and methyl; wherein each of R11 and R12 is independently selected from hydrido, alkyl and phenyl; wherein m is zero; and wherein n is a number selected from zero through three; or a pharmaceutically-acceptable salt thereof.

  通常被描述为丙炔基甘氨酸氨基丙炔二醇衍生物的化合物，可用于治疗通过抑制血浆肾素活性介导的疾病。特别感兴趣的化合物是符合以下式I的化合物 其中A从CO和SO2中选择，X从氧原子和亚甲基中选择；R1和R9中的每一个独立选择自氢、甲基、乙基、正丙基、异丙基、苄基、三氟乙基、叔丁氧羰基和甲氧甲基羰基的基团，R1和R9附着的氮原子可以与氧结合形成N-氧化物；R2从氢、甲基、乙基和异丙基中选择；R3从苄基、环己基甲基、苯乙基、咪唑基甲基、吡啶基甲基和2-吡啶基乙基中选择；R5和R8中的每一个独立地是丙炔基或含丙炔基的基团；R7是环己基甲基；R4和R6中的每一个独立选择自氢和甲基；R11和R12中的每一个独立选择自氢、烷基和苯基；m为零；n为从零到三中选择的数字；或其药用可接受盐。
• Learning from Peptides to Access Functional Precision Polymer Sequences
  作者：Eva Maron、Jordan H. Swisher、Joris J. Haven、Tara Y. Meyer、Tanja Junkers、Hans G. Börner

  DOI：10.1002/anie.201902217

  日期：2019.7.29

  Functional precision polymers based on monodisperse oligo(N‐substituted acrylamide)s and oligo(2‐substituted‐α‐hydroxy acid)s have been synthesized. The discrete sequences originate from a direct translation of side‐chain functionality sequences of a peptide with well‐studied properties. The peptide was previously selected to solubilize the photosensitizer meta‐tetra(hydroxyphenyl)chlorin. The resulting

  合成了基于单分散低聚（N-取代的丙烯酰胺）和低聚（2-取代-α-羟基酸）的功能精密聚合物。离散序列源自具有良好研究性质的肽的侧链功能序列的直接翻译。先前已选择该肽来增溶光敏剂间四（羟苯基）二氢卟酚。所得拟肽制剂添加剂保留了母体肽的药物增溶和释放特性。在某些情况下，可以获得卓越的性能，可将最高有效负载量提高40％，并将初始药物释放速度提高27倍。